Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 17.9% on Thursday . The company traded as high as C$0.33 and last traded at C$0.33. Approximately 1,140,716 shares changed hands during trading, an increase of 72% from the average daily volume of 663,769 shares. The stock had previously closed at C$0.28.
Hemostemix Stock Up 25.0 %
The company has a market cap of C$30.49 million, a price-to-earnings ratio of -17.50 and a beta of 0.20. The business’s fifty day simple moving average is C$0.12 and its two-hundred day simple moving average is C$0.09.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- What Does a Stock Split Mean?
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Are Penny Stocks a Good Fit for Your Portfolio?
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
